Nigeria vs World: Adults (ages 15+) and children (ages 0-14) newly infected with HIV
Nigeria
48,000
in 2024
World
1.30 million
in 2024
Nigeria rank
4th
World rank
1st
Adults (ages 15+) and children (ages 0-14) newly infected with HIV over time
- Nigeria
- World
How they compare
World currently reports 1.30 million against 48,000 in Nigeria, a difference of 1.25 million.
That makes World's figure about 27.1 times Nigeria's.
Across all 35 years both countries report, World has been ahead every year.
Nigeria ranks 4th and World ranks 1st of 146 countries.
World has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Nigeria | World | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 187,000 | 3.09 million | 2.90 million | World |
| 2000s | 175,000 | 2.53 million | 2.35 million | World |
| 2010s | 113,600 | 1.89 million | 1.78 million | World |
| 2020s | 64,000 | 1.42 million | 1.36 million | World |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher adults (ages 15+) and children (ages 0-14) newly infected with hiv, Nigeria or World?
- World, at 1.30 million against 48,000 in Nigeria as of 2024.
- What is the difference in adults (ages 15+) and children (ages 0-14) newly infected with hiv between Nigeria and World?
- 1.25 million, with World ahead.
- How many years of comparable data are there for Nigeria and World?
- 35 years are reported by both, from 1990 to 2024.
- How do Nigeria and World rank globally for adults (ages 15+) and children (ages 0-14) newly infected with hiv?
- Nigeria ranks 4th and World ranks 1st of 146 countries.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Adults (ages 15+) and children (ages 0-14) newly infected with HIV. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of adults (ages 15+) and children (ages 0-14) newly infected with HIV.